Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 1
2015 2
2016 4
2017 5
2018 9
2019 6
2020 3
2021 2
2022 3
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW. Torres A, et al. Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16. Lancet Infect Dis. 2018. PMID: 29254862 Free article. Clinical Trial.
Serious adverse events occurred in 75 (19%) patients in the ceftazidime-avibactam group and 54 (13%) patients in the meropenem group. Four serious adverse events (all in the ceftazidime-avibactam group) were judged to be treatment related. INTERPRETATION: Ceftazidim …
Serious adverse events occurred in 75 (19%) patients in the ceftazidime-avibactam group and 54 (13%) patients in the meropenem group. …
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Carmeli Y, et al. Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20. Lancet Infect Dis. 2016. PMID: 27107460 Free article. Clinical Trial.
Patients were randomised (1:1) to 5-21 days of treatment with either ceftazidime-avibactam (a combination of 2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h) or best available therapy. ...No new safety concerns were i …
Patients were randomised (1:1) to 5-21 days of treatment with either ceftazidime-avibactam (a combination of 2000 mg ceftazidime plus …
Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T, Tsergouli K, Lowrie K. Karampatakis T, et al. Microb Pathog. 2023 Jun;179:106090. doi: 10.1016/j.micpath.2023.106090. Epub 2023 Mar 31. Microb Pathog. 2023. PMID: 37004964 Review.
However, novel antimicrobials have been recently launched. Ceftazidime-avibactam (CAZ-AVI) seems one of the most efficient ones. AIM: The aim of the current systematic literature review and meta-analysis is to assess the efficacy and safety of CAZ-AVI compared to other ant …
However, novel antimicrobials have been recently launched. Ceftazidime-avibactam (CAZ-AVI) seems one of the most efficient ones. AIM: …
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Wagenlehner FM, et al. Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16. Clin Infect Dis. 2016. PMID: 27313268 Free PMC article. Clinical Trial.
The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis. ...Both treatments showed similar efficacy against ceftazidime-nonsusceptible …
The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with complicated ur …
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Mazuski JE, et al. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. Clin Infect Dis. 2016. PMID: 26962078 Free PMC article. Clinical Trial.
BACKGROUND: When combined with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. ...Adverse events were similar between groups. CONCLUSIONS: Ceftazidime-avibactam plus …
BACKGROUND: When combined with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem altern …
Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis.
Chen Y, Huang HB, Peng JM, Weng L, Du B. Chen Y, et al. Microbiol Spectr. 2022 Apr 27;10(2):e0260321. doi: 10.1128/spectrum.02603-21. Epub 2022 Apr 4. Microbiol Spectr. 2022. PMID: 35377233 Free PMC article.
Several clinicians use ceftazidime-avibactam (CAZ-AVI) to treat bloodstream infections (BSIs) due to carbapenem-resistant Enterobacterales (CRE), although no conclusive data support this practice. ...Although the current study is based on observational studies with a small …
Several clinicians use ceftazidime-avibactam (CAZ-AVI) to treat bloodstream infections (BSIs) due to carbapenem-resistant Enterobacte …
Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.
Chen J, Hu Q, Zhou P, Deng S. Chen J, et al. Infection. 2024 Feb;52(1):19-28. doi: 10.1007/s15010-023-02108-6. Epub 2023 Oct 25. Infection. 2024. PMID: 37878197 Free PMC article. Review.
We aimed to compare the efficacy and the safety of ceftazidime-avibactam (CAZ-AVI) and polymyxin in the treatment of CRE infections. ...
We aimed to compare the efficacy and the safety of ceftazidime-avibactam (CAZ-AVI) and polymyxin in the treatment of CRE infections. …
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-beta-lactamase production: a systematic review and meta-analysis.
Gupta N, Boodman C, Prayag P, Manesh A, Kumar TP. Gupta N, et al. Expert Rev Anti Infect Ther. 2024 Apr;22(4):203-209. doi: 10.1080/14787210.2024.2307912. Epub 2024 Feb 8. Expert Rev Anti Infect Ther. 2024. PMID: 38258529 Review.
INTRODUCTION: Carbapenem-resistant Enterobacterales (CRE) due to Metallo-beta-lactamase (MBL) production are treated with either polymyxins or the novel combination of ceftazidime-avibactam and aztreonam (AA). This study aims to evaluate the 30-day mortality of AA in patie …
INTRODUCTION: Carbapenem-resistant Enterobacterales (CRE) due to Metallo-beta-lactamase (MBL) production are treated with either polymyxins …
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
Torres A, Wible M, Tawadrous M, Irani P, Stone GG, Quintana A, Debabov D, Burroughs M, Bradford PA, Kollef M. Torres A, et al. J Antimicrob Chemother. 2023 Nov 6;78(11):2672-2682. doi: 10.1093/jac/dkad280. J Antimicrob Chemother. 2023. PMID: 37700689 Clinical Trial.
Clinical cure rates in the pooled non-MBL beta-lactamase-producing mMITT population were 88.1% (334/379) for ceftazidime/avibactam and 88.1% (364/413) for comparators; favourable microbiological response rates were 76.5% (290/379) and 68.8% (284/413), respectively. The saf …
Clinical cure rates in the pooled non-MBL beta-lactamase-producing mMITT population were 88.1% (334/379) for ceftazidime/avibactam an …
Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis.
Yang P, Li Y, Wang X, Chen N, Lu X. Yang P, et al. BMJ Open. 2023 May 3;13(5):e070491. doi: 10.1136/bmjopen-2022-070491. BMJ Open. 2023. PMID: 37137556 Free PMC article.
OBJECTIVES: Carbapenem-resistant Enterobacteriaceae is increasingly recognised as a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) and polymyxins are considered as the last therapeutic options worldwide. ...
OBJECTIVES: Carbapenem-resistant Enterobacteriaceae is increasingly recognised as a significant public health concern. Ceftazidime-avibac …
47 results

Searches related to "avibactam"